GGrantIndex
← Search

DEVELOPMENTAL FUNDS (Core-002)

$4,736P30FY2018CANIH

Vanderbilt University Medical Center, Nashville TN

Investigators

Linked publications, trials & patents

Trial NCT07016399Trial NCT06593106Trial NCT05501665Trial NCT05361720Trial NCT04765072Trial NCT02702310Trial NCT02685631Trial NCT02677883Trial NCT02676752Trial NCT02672475Trial NCT02658487Trial NCT02600533Trial NCT02489422Trial NCT02480114Trial NCT02457910Trial NCT02448225Trial NCT02440737Trial NCT02374931Trial NCT02359851Trial NCT02324881Trial NCT02296112Trial NCT02269111Trial NCT02240381Trial NCT02236546Trial NCT02170272Trial NCT02151539Trial NCT02148406Trial NCT01996527Trial NCT01928160Trial NCT01901367Trial NCT01660971Trial NCT01230515Trial NCT01198535Trial NCT01141218Trial NCT01098669Trial NCT01098643Trial NCT01096407Trial NCT01096394Trial NCT01096381Trial NCT01077440Trial NCT01031446Trial NCT01013506Trial NCT01009931Trial NCT01007422Trial NCT00993694Trial NCT00993135Trial NCT00987766Trial NCT00984542Trial NCT00984490Trial NCT00983268Trial NCT00957736Trial NCT00949052Trial NCT00930930Trial NCT00900406Trial NCT00900003Trial NCT00899769Trial NCT00899626Trial NCT00899457Trial NCT00899301Trial NCT00899028Trial NCT00898742Trial NCT00898638Trial NCT00898430Trial NCT00898313Trial NCT00897988Trial NCT00897832Trial NCT00897793Trial NCT00897650Trial NCT00897468Trial NCT00897403Trial NCT00897117Trial NCT00896948Trial NCT00896675Trial NCT00892801Trial NCT00875238Trial NCT00840814Trial NCT00837876Trial NCT00835679Trial NCT00801346Trial NCT00765245Trial NCT00755040Trial NCT00675636Trial NCT00670644Trial NCT00670605Trial NCT00670046Trial NCT00666211Trial NCT00656604Trial NCT00653250Trial NCT00651976Trial NCT00651716Trial NCT00647218Trial NCT00626873Trial NCT00625417Trial NCT00625066Trial NCT00616590Trial NCT00601991Trial NCT00573404Trial NCT00550537Trial NCT00544648Trial NCT00533884

Abstract

CORE 002 - DEVELOPMENTAL FUNDS PROJECT SUMMARY/ABSTRACT Although we have witnessed tremendous success in our cancer clinics in the past five years, over half of our patients will receive frontline treatments that are more than 25 years old. That sobering statistic indicates that we must continue to recruit the next generation of cancer scientists and continue to innovate in our labs and our shared resources. Developmental Funds provide essential support for the Vanderbilt-Ingram Cancer Center's (VICC) strategic initiatives. During the current project period, this support was applied towards recruitment of new faculty and for support of pilot projects. A total of eight new faculty members were provided with recruitment support; including a key strategic recruitment to underscore our commitment to smoking cessation. A total of 11 pilot projects were funded over the project period with a significant publication and a subsequent funding of next to 20-fold more than initially invested. $102,498 per year would be allocated for new faculty recruitment in targeted strategic areas, including but not limited to cancer genetics, genomics and epigenetics, cancer drug discovery, personalized cancer medicine, phase I investigations, cancer epidemiology and population-based research, cancer control and hematologic and neurologic malignancies. A request of $200,000 per year will support three types of pilot projects: 1) highly innovative projects focusing on proof-of- concept or translational research, 2) preliminary collaborative investigations leading to multi-investigator grants, and 3) projects that closely align to our strategic plan in order to enhance key initiatives. Developmental funds will also be used to support seven staff investigators in clinical, basic, population and disparities research. The VICC has a proven track record in the stewardship of these funds. The current request, in concert with the continued commitment of VICC discretionary funds, enables the Director to support activities critical to the sustained research excellence of the VICC.

View original record on NIH RePORTER →